Integrating Bone Targeting Radiopharmaceuticals Into the Management of Patients With Castrate-Resistant Prostate Cancer With Symptomatic Bone Metastases

详细信息    查看全文

• 作者：Seth R. Blacksburg MD ; MBA (1)
  Matthew R. Witten PhD (1)
  Jonathan A. Haas MD (1)
  
  1. Winthrop-University Hospital ; 259 First Street ; Mineola ; NY ; 11501 ; USA
  
• 关键词：Prostate cancer ; Castrate ; resident prostate cancer ; Radium ; 223 ; Xofigo ; Radiopharmaceuticals ; Alpha emitters
• 刊名：Current Treatment Options in Oncology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：16
• 期：3
• 全文大小：791 KB
• 参考文献：1. American Cancer Society. Prostate Cancer. 2013.
  2. Coleman, RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: pp. 6243s-6249s CrossRef
  3. N酶rgaard M, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007) / . J Urol. 184(1):162-167.
  4. Hess, KR (2006) Metastatic patterns in adenocarcinoma. Cancer 106: pp. 1624-1633 CrossRef
  5. Fizazi, K (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377: pp. 813-822 CrossRef
  6. Lage, MJ (2008) The cost of treating skeletal-related events in patients with prostate cancer. Am J Manage Care 14: pp. 317-322
  7. Zustovich, F, Fabiani, F (2014) Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. Crit Rev Oncol Hematol 91: pp. 197-209 CrossRef
  8. From ASCO-prostate cancer: Chemohormonal therapy leads the way in prostate cancer. Nat Rev Clin Oncol. 2014;11(7):380. The E3805 trial was presented at ASCO 2014 and is practice changing. Although the subject of this study is beyond the scope of this review, the change in practice has future implications on the use of many of the CRPC modalities and sequencing.
  9. Tannock, IF (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: pp. 1502-1512 CrossRef
  10. Hartsell, WF (2005) Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97: pp. 798-804 CrossRef
  11. Steenland, E (1999) The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch bone metastasis study. Radiother Oncol 52: pp. 101-109 CrossRef
  12. Linden, YM (2004) Single fraction radiotherapy is efficacious: a further analysis of the Dutch bone metastasis study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 59: pp. 528-537 CrossRef
  13. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone pain trial working party. Radiother Oncol. 1999;52(2):111-21.
  14. Lutz, S (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79: pp. 965-976 CrossRef
  15. Roach, M (2014) Radium-223 vs EBRT for multiple painful bone metastases: is less more?. Oncology (Williston Park) 28: pp. 297-298
  16. Salazar, OM (2001) Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 50: pp. 765-775 CrossRef
  17. Ki, Y (2011) Fractionated wide-field radiation therapy followed by fractionated local-field irradiation for treating widespread painful bone metastasis. Int J Radiat Oncol Biol Phys 79: pp. 220-225 CrossRef
  18. Yamada, Y (2008) High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71: pp. 484-490 CrossRef
  19. Gerszten, PC (2007) Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 32: pp. 193-199 CrossRef
  20. Rades, D, Schild, SE (2007) Is stereotactic radiosurgery the best treatment option for patients with spinal metastases?. Nat Clin Pract Oncol 4: pp. 400-401 CrossRef
  21. Gagnon, GJ (2007) Cyberknife radiosurgery for breast cancer spine metastases: a matched-pair analysis. Cancer 110: pp. 1796-1802 CrossRef
  22. Sahgal, A (2009) Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys 74: pp. 723-731 CrossRef
  23. Sahgal, A (2013) Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol 31: pp. 3426-3431 CrossRef
  24. Sahgal, A (2013) Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol 14: pp. e310-e320 CrossRef
  25. Rose, PS (2009) Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 27: pp. 5075-5079 CrossRef
  26. Ryu, S (2014) RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results. Pract Radiat Oncol 4: pp. 76-81 CrossRef
  27. Roque, M (2003) Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 4:
  28. Vapiwala, N, Glatstein, E (2013) Fighting prostate cancer with radium-223鈥搉ot your Madame's isotope. N Engl J Med 369: pp. 276-278 CrossRef
  29. Janjan, N (2009) Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of radiology appropriateness criteria expert panel on radiation oncology. J Palliat Med 12: pp. 417-426 CrossRef
  30. Pandit-Taskar, N, Batraki, M, Divgi, CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45: pp. 1358-1365
  31. Porter, AT (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25: pp. 805-813 CrossRef
  32. Quilty, PM (1994) A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31: pp. 33-40 CrossRef
  33. Zorga, P (2011) Effectiveness of strontium-89 palliative therapy in patients with painful bone metastases. Ann Acad Med Stetin 57: pp. 49-53
  34. James N, et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both. J Clin Oncol, 2013;31 no. 15_suppl LBA5000.
  35. Serafini, AN (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16: pp. 1574-1581
  36. Sartor, O (2004) Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63: pp. 940-945 CrossRef
  37. Bruland, OS (2006) High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?. Clin Cancer Res 12: pp. 6250s-6257s CrossRef
  38. Xofigo庐 (radium Ra 223 dichloride) injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; May 2013.
  39. Parker, C (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369: pp. 213-223 CrossRef
  40. Sartor, O (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15: pp. 738-746 CrossRef
  41. Nilsson S, et al. Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating pain relief from the phase 3 ALSYMPCA study. J Clin Oncol. 2014;32:5s, 2014 (suppl; abstr 5069).
  42. Nilsson, S, Vogelzang, N, Sartor, AO (2014) 1.5-Year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study 9. Clin Adv Hematol Oncol 12: pp. 9-10
  43. D'Amico, AV (2014) US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol 32: pp. 362-364 CrossRef
  44. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)庐. Prostate Cancer. Version 4. 2013.
  45. Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms; NCT02043678. ClinicalTrials.gov, 2014.
  46. Saad, F (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: pp. 879-882 CrossRef
  47. Tran, C (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: pp. 787-790 CrossRef
  48. Scher, HI (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: pp. 1187-1197 CrossRef
  49. Bono, JS (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: pp. 1995-2005 CrossRef
  50. Fizazi, K (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13: pp. 983-992 CrossRef
  51. Logothetis, CJ (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13: pp. 1210-1217 CrossRef
  52. Ryan, CJ (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: pp. 138-148 CrossRef
  
• 刊物主题：Oncology;
• 出版者：Springer US
• ISSN：1534-6277

文摘